The Firm recently represented the underwriters, led by Banc of America Securities LLC, Deutsche Bank Securities Inc. and J.P. Morgan Securities Inc., in connection with the public offering by Boston Scientific Corporation (“Boston Scientific”) of $2 billion of debt securities, consisting of $850 million of 4.500% Senior Notes due 2015, $850 million of 6.000% Senior Notes due 2020 and $300 million of 7.375% Senior Notes due 2040. Boston Scientific will use the net proceeds from the offering for general corporate purposes, including prepaying its bank term loan due in April 2011.
Boston Scientific, a Delaware corporation, is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties, including interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology and neuromodulation.
The Simpson Thacher team for the transaction included Vince Pagano, Mark Brod, Elsa Wang and Jeemin Chung (Capital Markets), Paul Gluckow, Sarah Dunn and Abby Mollen (Litigation), Bob Bourque and Alex Key (IP Litigation), Marcela Robledo and Noah Richmond (Intellectual Property), Jonathan Cantor (Tax), Michael Isby (Environmental) and Andrew Pagliughi (Blue Sky). Paralegal Matt Dresher provided valuable assistance.